Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Dynamic Changes in Gene Mutational Landscape With Preservation of Core Mutations in Mantle Cell Lymphoma Cells.

Zhang Q, Wang HY, Liu X, Roth MH, Shestov AA, Lee SC, Jain K, Soderquist C, Xiong QB, Ruella M, Strauser H, Glickson JD, Schuster SJ, Ptasznik A, Wasik MA.

Front Oncol. 2019 Jul 3;9:568. doi: 10.3389/fonc.2019.00568. eCollection 2019.

2.

Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.

Lee SC, Shestov AA, Guo L, Zhang Q, Roman JC, Liu X, Wang HY, Pickup S, Nath K, Lu P, Hofbauer S, Mesaros C, Wang YL, Nelson DS, Schuster SJ, Blair IA, Glickson JD, Wasik MA.

Mol Cancer Res. 2019 Jun;17(6):1365-1377. doi: 10.1158/1541-7786.MCR-18-0256. Epub 2019 Mar 12.

PMID:
30862686
3.

Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.

Nath K, Roman J, Nelson DS, Guo L, Lee SC, Orlovskiy S, Muriuki K, Heitjan DF, Pickup S, Leeper DB, Blair IA, Putt ME, Glickson JD.

Sci Rep. 2018 Oct 2;8(1):14654. doi: 10.1038/s41598-018-33019-4.

4.

Drug repurposing for the treatment of glioblastoma multiforme.

Abbruzzese C, Matteoni S, Signore M, Cardone L, Nath K, Glickson JD, Paggi MG.

J Exp Clin Cancer Res. 2017 Nov 28;36(1):169. doi: 10.1186/s13046-017-0642-x. Review.

5.

Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.

Nath K, Nelson DS, Roman J, Putt ME, Lee SC, Leeper DB, Glickson JD.

Anticancer Res. 2017 Jul;37(7):3413-3421.

PMID:
28668829
6.

Mechanism of antineoplastic activity of lonidamine.

Nath K, Guo L, Nancolas B, Nelson DS, Shestov AA, Lee SC, Roman J, Zhou R, Leeper DB, Halestrap AP, Blair IA, Glickson JD.

Biochim Biophys Acta. 2016 Dec;1866(2):151-162. doi: 10.1016/j.bbcan.2016.08.001. Epub 2016 Aug 4. Review.

7.
8.

(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.

Shestov AA, Lee SC, Nath K, Guo L, Nelson DS, Roman JC, Leeper DB, Wasik MA, Blair IA, Glickson JD.

Front Oncol. 2016 Jun 15;6:135. doi: 10.3389/fonc.2016.00135. eCollection 2016.

9.

Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice.

Nath K, Nelson DS, Putt ME, Leeper DB, Garman B, Nathanson KL, Glickson JD.

PLoS One. 2016 Jun 10;11(6):e0157125. doi: 10.1371/journal.pone.0157125. eCollection 2016.

10.

The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.

Nancolas B, Guo L, Zhou R, Nath K, Nelson DS, Leeper DB, Blair IA, Glickson JD, Halestrap AP.

Biochem J. 2016 Apr 1;473(7):929-36. doi: 10.1042/BJ20151120. Epub 2016 Feb 1.

11.

Bonded Cumomer Analysis of Human Melanoma Metabolism Monitored by 13C NMR Spectroscopy of Perfused Tumor Cells.

Shestov AA, Mancuso A, Lee SC, Guo L, Nelson DS, Roman JC, Henry PG, Leeper DB, Blair IA, Glickson JD.

J Biol Chem. 2016 Mar 4;291(10):5157-71. doi: 10.1074/jbc.M115.701862. Epub 2015 Dec 24.

12.

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine.

Guo L, Shestov AA, Worth AJ, Nath K, Nelson DS, Leeper DB, Glickson JD, Blair IA.

J Biol Chem. 2016 Jan 1;291(1):42-57. doi: 10.1074/jbc.M115.697516. Epub 2015 Oct 31.

13.

Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts and sensitization to melphalan.

Nath K, Nelson DS, Heitjan DF, Zhou R, Leeper DB, Glickson JD.

NMR Biomed. 2015 Mar;28(3):395-403. doi: 10.1002/nbm.3260.

14.

Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Nath K, Nelson DS, Heitjan DF, Leeper DB, Zhou R, Glickson JD.

NMR Biomed. 2015 Mar;28(3):281-90. doi: 10.1002/nbm.3240. Epub 2014 Dec 12.

15.

The aspartate metabolism pathway is differentiable in human hepatocellular carcinoma: transcriptomics and (13) C-isotope based metabolomics.

Darpolor MM, Basu SS, Worth A, Nelson DS, Clarke-Katzenberg RH, Glickson JD, Kaplan DE, Blair IA.

NMR Biomed. 2014 Apr;27(4):381-9. doi: 10.1002/nbm.3072. Epub 2014 Feb 4.

16.

Is higher lactate an indicator of tumor metastatic risk? A pilot MRS study using hyperpolarized (13)C-pyruvate.

Xu HN, Kadlececk S, Profka H, Glickson JD, Rizi R, Li LZ.

Acad Radiol. 2014 Feb;21(2):223-31. doi: 10.1016/j.acra.2013.11.014.

17.

Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma.

Arias-Mendoza F, Payne GS, Zakian K, Stubbs M, O'Connor OA, Mojahed H, Smith MR, Schwarz AJ, Shukla-Dave A, Howe F, Poptani H, Lee SC, Pettengel R, Schuster SJ, Cunningham D, Heerschap A, Glickson JD, Griffiths JR, Koutcher JA, Leach MO, Brown TR.

Acad Radiol. 2013 Sep;20(9):1122-9. doi: 10.1016/j.acra.2013.04.013.

18.

Mapping the redox state of CHOP-treated non-Hodgkin's lymphoma xenografts in mice.

Xu HN, Mir TA, Lee SC, Feng M, Farhad N, Choe R, Glickson JD, Li LZ.

Adv Exp Med Biol. 2013;789:243-249. doi: 10.1007/978-1-4614-7411-1_33.

19.

CHOP THERAPY INDUCED MITOCHONDRIAL REDOX STATE ALTERATION IN NON-HODGKIN'S LYMPHOMA XENOGRAFTS.

Xu HN, Zhao H, Mir TA, Lee SC, Feng M, Choe R, Glickson JD, Li LZ.

J Innov Opt Health Sci. 2013 Apr;6(2):1350011.

20.

Impact of transvascular and cellular-interstitial water exchange on dynamic contrast-enhanced magnetic resonance imaging estimates of blood to tissue transfer constant and blood plasma volume.

Paudyal R, Poptani H, Cai K, Zhou R, Glickson JD.

J Magn Reson Imaging. 2013 Feb;37(2):435-44. doi: 10.1002/jmri.23837. Epub 2012 Nov 29.

PMID:
23197427
21.

Human Hepatocellular Carcinoma Metabolism: Imaging by Hyperpolarized 13C Magnetic Resonance Spectroscopy.

Darpolor MM, Kaplan DE, Pedersen PL, Glickson JD.

J Liver Disease Transplant. 2012 Sep 1;1(1). doi: 10.4172/2325-9612.1000101.

22.

Metabolic network analysis of DB1 melanoma cells: how much energy is derived from aerobic glycolysis?

Shestov AA, Mancuso A, Leeper DB, Glickson JD.

Adv Exp Med Biol. 2013;765:265-271. doi: 10.1007/978-1-4614-4989-8_37.

PMID:
22879043
23.

Lactate detection in inducible and orthotopic Her2/neu mammary gland tumours in mouse models.

Magnitsky S, Belka GK, Sterner C, Pickup S, Chodosh LA, Glickson JD.

NMR Biomed. 2013 Jan;26(1):35-42. doi: 10.1002/nbm.2816. Epub 2012 Jul 5.

24.

(31) P and (1) H MRS of DB-1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan.

Nath K, Nelson DS, Ho AM, Lee SC, Darpolor MM, Pickup S, Zhou R, Heitjan DF, Leeper DB, Glickson JD.

NMR Biomed. 2013 Jan;26(1):98-105. doi: 10.1002/nbm.2824. Epub 2012 Jun 29.

25.

Prediction and Early Detection of Response by NMR Spectroscopy and Imaging.

Lee SC, Arias-Mendoza F, Poptani H, Delikatny EJ, Wasik M, Marzec M, Schuster SJ, Nasta SD, Svoboda J, O'Connor OA, Smith MR, Glickson JD.

PET Clin. 2012 Jan;7(1):119-26. doi: 10.1016/j.cpet.2011.12.007. No abstract available.

26.

Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B-cell lymphoma.

Lee SC, Marzec M, Liu X, Wehrli S, Kantekure K, Ragunath PN, Nelson DS, Delikatny EJ, Glickson JD, Wasik MA.

NMR Biomed. 2013 Jan;26(1):106-14. doi: 10.1002/nbm.2825. Epub 2012 Jun 18.

27.

Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo.

Marotta DE, Cao W, Wileyto EP, Li H, Corbin I, Rickter E, Glickson JD, Chance B, Zheng G, Busch TM.

Nanomedicine (Lond). 2011 Apr;6(3):475-87. doi: 10.2217/nnm.11.8.

28.

In vivo and ex vivo MR imaging of slowly cycling melanoma cells.

Magnitsky S, Roesch A, Herlyn M, Glickson JD.

Magn Reson Med. 2011 Nov;66(5):1362-73. doi: 10.1002/mrm.22917. Epub 2011 Apr 26.

29.

NMR metabolic and physiological markers of therapeutic response.

Lee SC, Poptani H, Delikatny EJ, Pickup S, Nelson DS, Schuster SJ, Nasta SD, Svoboda J, Goldstein SC, Wallace SG, Loevner LA, Mellon EA, Reddy R, Glickson JD.

Adv Exp Med Biol. 2011;701:129-35. doi: 10.1007/978-1-4419-7756-4_18.

PMID:
21445779
30.

³¹P-MRS studies of melanoma xenografts with different metastatic potential.

Li LZ, Zhou R, Leeper DB, Glickson JD.

Adv Exp Med Biol. 2011;701:69-73. doi: 10.1007/978-1-4419-7756-4_10.

31.

Early detection of radiation therapy response in non-Hodgkin's lymphoma xenografts by in vivo 1H magnetic resonance spectroscopy and imaging.

Lee SC, Poptani H, Pickup S, Jenkins WT, Kim S, Koch CJ, Delikatny EJ, Glickson JD.

NMR Biomed. 2010 Jul;23(6):624-32. doi: 10.1002/nbm.1505.

PMID:
20661875
32.

Quantitative mitochondrial redox imaging of breast cancer metastatic potential.

Xu HN, Nioka S, Glickson JD, Chance B, Li LZ.

J Biomed Opt. 2010 May-Jun;15(3):036010. doi: 10.1117/1.3431714.

33.

Detection of lactate with a hadamard slice selected, selective multiple quantum coherence, chemical shift imaging sequence (HDMD-SelMQC-CSI) on a clinical MRI scanner: Application to tumors and muscle ischemia.

Mellon EA, Lee SC, Pickup S, Kim S, Goldstein SC, Floyd TF, Poptani H, Delikatny EJ, Reddy R, Glickson JD.

Magn Reson Med. 2009 Dec;62(6):1404-13. doi: 10.1002/mrm.22141.

34.

Quantitative magnetic resonance and optical imaging biomarkers of melanoma metastatic potential.

Li LZ, Zhou R, Xu HN, Moon L, Zhong T, Kim EJ, Qiao H, Reddy R, Leeper D, Chance B, Glickson JD.

Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6608-13. doi: 10.1073/pnas.0901807106. Epub 2009 Apr 6.

35.

Histological basis of MR/optical imaging of human melanoma mouse xenografts spanning a range of metastatic potentials.

Xu HN, Zhou R, Nioka S, Chance B, Glickson JD, Li LZ.

Adv Exp Med Biol. 2009;645:247-53. doi: 10.1007/978-0-387-85998-9_37.

36.

Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents.

Glickson JD, Lund-Katz S, Zhou R, Choi H, Chen IW, Li H, Corbin I, Popov AV, Cao W, Song L, Qi C, Marotta D, Nelson DS, Chen J, Chance B, Zheng G.

Adv Exp Med Biol. 2009;645:227-39. doi: 10.1007/978-0-387-85998-9_35.

PMID:
19227476
37.

Reduced oxygenation in diabetic rat kidneys measured by T2* weighted magnetic resonance micro-imaging.

Edlund J, Hansell P, Fasching A, Liss P, Weis J, Glickson JD, Palm F.

Adv Exp Med Biol. 2009;645:199-204. doi: 10.1007/978-0-387-85998-9_31.

PMID:
19227472
38.

Imaging of cardiotoxicity.

Glickson JD, Forder JR, Chatham JC.

Mol Imaging. 2008 May-Jun;7(3):115-7. No abstract available.

PMID:
19123981
39.

In vivo (1)H MRS of WSU-DLCL2 human non-Hodgkin's lymphoma xenografts: response to rituximab and rituximab plus CHOP.

Lee SC, Delikatny EJ, Poptani H, Pickup S, Glickson JD.

NMR Biomed. 2009 Apr;22(3):259-65. doi: 10.1002/nbm.1316.

PMID:
19040203
40.

Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI.

Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, Zhou R, Delikatny EJ, Poptani H, Glickson JD.

NMR Biomed. 2008 Nov;21(10):1021-9. doi: 10.1002/nbm.1261.

41.

Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents.

Glickson JD, Lund-Katz S, Zhou R, Choi H, Chen IW, Li H, Corbin I, Popov AV, Cao W, Song L, Qi C, Marotta D, Nelson DS, Chen J, Chance B, Zheng G.

Mol Imaging. 2008 Mar-Apr;7(2):101-10.

PMID:
18706292
42.

Lactate imaging with Hadamard-encoded slice-selective multiple quantum coherence chemical-shift imaging.

Pickup S, Lee SC, Mancuso A, Glickson JD.

Magn Reson Med. 2008 Aug;60(2):299-305. doi: 10.1002/mrm.21659.

43.

In vivo MRS markers of response to CHOP chemotherapy in the WSU-DLCL2 human diffuse large B-cell lymphoma xenograft.

Lee SC, Huang MQ, Nelson DS, Pickup S, Wehrli S, Adegbola O, Poptani H, Delikatny EJ, Glickson JD.

NMR Biomed. 2008 Aug;21(7):723-33. doi: 10.1002/nbm.1250.

PMID:
18384181
44.

In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS.

Huang MQ, Nelson DS, Pickup S, Qiao H, Delikatny EJ, Poptani H, Glickson JD.

Acad Radiol. 2007 Dec;14(12):1531-9.

45.

Transcytolemmal water exchange in pharmacokinetic analysis of dynamic contrast-enhanced MRI data in squamous cell carcinoma of the head and neck.

Kim S, Quon H, Loevner LA, Rosen MA, Dougherty L, Kilger AM, Glickson JD, Poptani H.

J Magn Reson Imaging. 2007 Dec;26(6):1607-17.

PMID:
17968962
46.

Predicting melanoma metastatic potential by optical and magnetic resonance imaging.

Li LZ, Zhou R, Zhong T, Moon L, Kim EJ, Qiao H, Pickup S, Hendrix MJ, Leeper D, Chance B, Glickson JD.

Adv Exp Med Biol. 2007;599:67-78.

47.

Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo.

Chen J, Corbin IR, Li H, Cao W, Glickson JD, Zheng G.

J Am Chem Soc. 2007 May 9;129(18):5798-9. Epub 2007 Apr 12. No abstract available.

PMID:
17428054
48.

Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents.

Corbin IR, Li H, Chen J, Lund-Katz S, Zhou R, Glickson JD, Zheng G.

Neoplasia. 2006 Jun;8(6):488-98.

49.

In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial.

Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, Ballon D, Howe FA, Koutcher JA, Leach MO, Griffiths JR, Heerschap A, Glickson JD, Nelson SJ, Evelhoch JL, Charles HC, Brown TR.

NMR Biomed. 2006 Jun;19(4):504-12.

PMID:
16763965
50.

Creatine kinase, a magnetic resonance-detectable marker gene for quantification of liver-directed gene transfer.

Li Z, Qiao H, Lebherz C, Choi SR, Zhou X, Gao G, Kung HF, Rader DJ, Wilson JM, Glickson JD, Zhou R.

Hum Gene Ther. 2005 Dec;16(12):1429-38.

PMID:
16390274

Supplemental Content

Loading ...
Support Center